KROS vs. SRRA, SRRK, YMAB, DRNA, AMRN, BPMC, JAZZ, BBIO, IONS, and OGN
Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Sierra Oncology (SRRA), Scholar Rock (SRRK), Y-mAbs Therapeutics (YMAB), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Blueprint Medicines (BPMC), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Ionis Pharmaceuticals (IONS), and Organon & Co. (OGN). These companies are all part of the "medical" sector.
Sierra Oncology (NASDAQ:SRRA) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
Keros Therapeutics has a consensus target price of $86.00, indicating a potential upside of 83.49%. Given Sierra Oncology's higher probable upside, analysts clearly believe Keros Therapeutics is more favorable than Sierra Oncology.
Sierra Oncology's return on equity of -45.53% beat Keros Therapeutics' return on equity.
Sierra Oncology received 261 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 67.49% of users gave Sierra Oncology an outperform vote while only 66.67% of users gave Keros Therapeutics an outperform vote.
99.3% of Sierra Oncology shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 44.1% of Sierra Oncology shares are held by insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sierra Oncology has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.
Sierra Oncology has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Sierra Oncology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Keros Therapeutics had 5 more articles in the media than Sierra Oncology. MarketBeat recorded 5 mentions for Keros Therapeutics and 0 mentions for Sierra Oncology. Sierra Oncology's average media sentiment score of 0.92 beat Keros Therapeutics' score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the news media.
Summary
Keros Therapeutics beats Sierra Oncology on 9 of the 16 factors compared between the two stocks.
Get Keros Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Keros Therapeutics Competitors List
Related Companies and Tools
